BC
TPTX

Brookfield Corp’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Brookfield Corp’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-77,488
Closed -$2.08M – 778
2022
Q1 		$2.08M Buy
+77,488
New +$2.6M 0.01% 391

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Brookfield Corp's TPTX Position: Q2 2022 in Review

Brookfield Corp sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 77,488 shares — an estimated $2.08M sold.

Brookfield Corp first reported a position in TPTX in Q1 2022 and held it in 1 quarter. The position peaked at $2.08M in Q1 2022. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

  • Brookfield Corp reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Brookfield Corp sold 77,488 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $2.08M.
  • Brookfield Corp first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Brookfield Corp's Turning Point Therapeutics, Inc. Common Stock position peaked at $2.08M in Q1 2022.
  • 208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Brookfield Corp's 13F filing for Q2 2022, filed 15 Aug 2022.